Preview

Пульмонология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению

https://doi.org/10.18093/0869-0189-2022-32-3-356-392

Полный текст:

Аннотация

В настоящее время хроническая обструктивная болезнь легких (ХОБЛ) является глобальной проблемой и одной из ведущих причин смерти в мире. Терапия ХОБЛ включает фармакологические и нефармакологические подходы, которые позволяют существенно уменьшить клинические симптомы и снизить частоту обострений заболевания.

Методология. Целевой аудиторией данных клинических рекомендаций являются врачи-терапевты, врачи общей практики, врачи-пульмонологи. Каждый тезис-рекомендация по проведению диагностических и лечебных мероприятий оценивается по шкалам уровней достоверности доказательств от 1 до 5 и шкале оценки уровней убедительности рекомендаций по категориям А, В, С. Клинические рекомендации содержат также комментарии и разъяснения к указанным тезисам-рекомендациям, алгоритмы по тактике ведения пациентов с ХОБЛ.

Заключение. В представленных клинических рекомендациях приводятся современные сведения об этиологии и патогенезе, клинических проявлениях, диагностике, лечении ХОБЛ. Одобрены решением Научно-практического совета Министерства здравоохранения Российской Федерации (2021). 

Об авторах

А. Г. Чучалин
Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор, академик Российской академии наук, заведующий кафедрой госпитальной терапии педиатрического факультета,

117997, Россия, Москва, ул. Островитянова, 1

председатель правления Российского респираторного общества



С. Н. Авдеев
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства
Россия

д. м. н., профессор, академик Российской академии наук, заведующий кафедрой пульмонологии Института клинической медицины имени Н.В.Склифосовского, 119991,  Москва, ул. Трубецкая, 8, стр. 2;

ведущий научный сотрудник, 115682, Москва, Ореховый бульвар, 28



З. Р. Айсанов
Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор кафедры пульмонологии,

117997, Москва, ул. Островитянова, 1



А. С. Белевский
Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор, заведующий кафедрой пульмонологии,

117997, Москва, ул. Островитянова, 1



И. В. Лещенко
Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Уральский научно-исследовательский институт фтизиопульмонологии – филиал федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор кафедры фтизиатрии и пульмонологии, 620028, Екатеринбург, ул. Репина, 3;

главный научный сотрудник, 620039, Свердловская область, Екатеринбург, 22-го Партсъезда, 50



С. И. Овчаренко
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)
Россия

д. м. н., профессор кафедры факультетской терапии № 1,

119991, Москва, ул. Трубецкая, 8, стр. 2



Е. И. Шмелев
Федеральное государственное бюджетное научное учреждение «Центральный научно-исследовательский институт туберкулеза»
Россия

д. м. н., профессор, заведующий отделом дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения,

107564, Москва, Яузская аллея, 2



Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf

2. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 693–718. DOI: 10.1164/rccm.200811-1757ST.

3. Lamprecht B., McBurnie M.A., Vollmer W.M. et al. BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–763. DOI: 10.1378/chest.10-1253.

4. Mehta A.J., Miedinger D., Keidel D. et al. The SAPALDIA Team. Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am. J. Respir. Crit. Care Med. 2012; 185 (12): 1292–1300. DOI: 10.1164/rccm.201110-1917OC.

5. Silva G.E., Sherrill D.L., Guerra S. et al. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004; 126 (1): 59–65. DOI: 10.1378/chest.126.1.59.

6. Brutsche M.H., Downs S.H., Schindler C. et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006; 61 (8): 671–677. DOI: 10.1136/thx.2005.052241.

7. de Marco R., Accordini S., Marcon A. et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011; 183 (7): 891–897. DOI: 10.1164/rccm.201007-1125OC.

8. de Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175 (1): 32–39. DOI: 10.1164/rccm.200603-381OC.

9. Bridevaux P.O., Gerbase M.W., Probst-Hensch N.M. et al. Longterm decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008; 63 (9): 768–774. DOI: 10.1136/thx.2007.093724.

10. Stoller J.K. Clinical features and natural history of severe alpha-1-antitrypsin deficiency. Chest. 1997; 111 (6, Suppl.): 123–128S. DOI: 10.1378/chest.111.6_supplement.123s.

11. Stoller J.K., Aboussouan L.S. A review of alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2012; 185 (3): 246–259. DOI: 10.1164/rccm.201108-1428CI.

12. Smolonska J., Wijmenga C., Postma D.S., Boezen H.M. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years’ research. Am. J. Respir. Crit. Care Med. 2009; 180 (7): 618–631. DOI: 10.1164/rccm.200905-0722OC.

13. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9: 963–974. DOI: 10.2147/COPD.S67283.

14. World Health Organization. Evidence-informed policy-making. 2016. Available at: http://www.who.int/evidence

15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. Available at: www. goldcopd.com

16. Celli B., MacNee W., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946. DOI: 10.1183/09031936.04.00014304.

17. Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54 (7): 581–586. DOI: 10.1136/thx.54.7.581.

18. Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI: 10.1183/09031936.00102509.

19. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138. DOI: 10.1056/NEJMoa0909883.

20. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33 (5): 1165–1185. DOI: 10.1183/09031936.00128008.

21. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary diseaseamong patients at risk im primary care. CMAJ. 2010; 182 (7): 673–678. DOI: 10.1503/cmaj.091784.

22. Güder G., Brenner S., Angermann C.E. et al. “GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study”. Respir. Res. 2012; 13 (1): 13. DOI: 10.1186/1465-9921-13-13.

23. Bhatt S.P., Balte P.P., Schwartz J.E. et al. Discriminative accuracy of FEV1: FVC thresholds for COPD-related hospitalization and mortality. JAMA. 25; 321 (24): 2438–2447. DOI: 10.1001/jama.2019.7233.

24. Tashkin D.P., Celli B., Decramer M. et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008; 31 (4): 742–750. DOI: 10.1183/09031936.00129607.

25. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40. DOI: 10.1183/09041950.005s1693.

26. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir J. 2005; 26 (3): 511–522. DOI: 10.1183/09031936.05.00035005.

27. Amalakanti S., Pentakota M.R. Pulse oximetry overestimates oxygen saturtion in COPD. Respir Care. 2016; 61 (4): 423–427. DOI: 10.4187/respcare.04435.

28. Casanova C., Cote C.G., Marin J.M. et al. Test 6-min walking distance: long-term follow up in patients with COPD. Eur. Respir. J. 2007; 29 (3): 535–540. DOI: 10.1183/09031936.00071506.

29. Oga T., Nishimura K., Tsukino M. et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003; 167 (4): 544–549. DOI: 10.1164/rccm.200206-583OC.

30. Kelly A.M., McAlpine R., Kyle E. How accurate are pulse oximeters in patients with acute exacerbationsof chronic obstructive airways disease? Respir. Med. 2001; 95 (5): 336–340. DOI: 10.1053/rmed.2001.1046.

31. Stoller J.K., Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD. 2013; 10 (Suppl. 1): 24–34. DOI: 10.3109/15412555.2013.763782.

32. Flenley D.C. Sleep in chronic obstructive lung disease. Clin. Chest Med. 1985; 4 (6): 651–661.

33. Буниатян М.С., Зелвеян П.А., Ощепкова Е.В. Возможности мониторной пульсоксиметрии для скрининговой диагностики синдрома апноэ/гипопноэ во сне. Терапевтический архив. 2002; 74 (11): 90–94.

34. Celli B., Cote C., Marin J. et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350 (10): 1005–1012. DOI: 10.1056/NEJMoa021322.

35. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. Available at: https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA-2017-main-report-final_V2.pdf

36. Albert P., Agusti A., Edwards L. et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012; 67 (8): 701–708. DOI: 10.1136/thoraxjnl-2011-201458.

37. Woolcock A.J. Corticosteroid-resistant asthma: definitions. Am. J. Respir. Crit. Care Med. 1996; 154 (2, Pt 2): 45–48. DOI: 10.1164/ajrccm/154.2_Pt_2.S45.

38. Pelkonen M., Notkola I.L., Tukiainen H. et al. Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow-up study among the Finnish cohorts of the Seven Countries Study. Thorax. 2001; 56 (9): 703–707. DOI: 10.1136/thorax.56.9.703.

39. Chandler M.A., Rennard S.I. Smoking cessation. Chest. 2010; 137 (2): 428–435. DOI: 10.1378/chest.09-0124.

40. Henningfield J.E. Nicotine medications for smoking cessation. N. Engl. J. Med. 1995; 333 (18): 1196–1203. DOI: 10.1056/NEJM199511023331807.

41. Jorenby D.E., Leischow S.J., Nides M.A. et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340 (9): 685–691. DOI: 10.1056/NEJM199903043400903.

42. Silagy C., Mant D., Fowler G., Lodge M. Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994; 343 (8890): 139–142. DOI: 10.1016/s0140-6736(94)90933-4.

43. Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001; 357 (9268): 1571–1575. DOI: 10.1016/s0140-6736(00)04724-3.

44. Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur. Respir. J. 2009; 34 (3): 634–640. DOI: 10.1183/09031936.00167708.

45. Faessel H., Ravva P., Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin. Ther. 2009; 31 (1): 177–189. DOI: 10.1016/j.clinthera.2009.01.003.

46. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV 1: The lung health study. JAMA. 1994; 272 (19): 1497–1505. DOI: 10.1001/jama.1994.03520190043033.

47. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009; 374 (9696): 1171–1178. DOI: 10.1016/S0140-6736(09)61298-8.

48. Jenkins C.R., Jones P.W., Calverley P.M. et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10 (1): 59. DOI: 10.1186/1465-9921-10-59.

49. Lipson D.A., Crim C., Criner G.J. et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2020; 201 (12): 1508–1516. DOI: 10.1164/rccm.201911-2207OC.

50. Sestini P., Renzoni E., Robinson S. et al. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002; (4): CD001495. DOI: 10.1002/14651858.CD001495.

51. Chung V.C.H., Ma P.H.X., Hui D.S.C. et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013; 8 (8): e70784. DOI: 10.1371/journal.pone.0070784.

52. Cope S., Donohue J.F., Jansen J.P. et al. Comparative efficacy of long-acting bronchodilators for COPD – a network meta-analysis. Respir. Res. 2013; 14 (1): 100. DOI: 10.1186/1465-9921-14-100.

53. Koch A., Pizzichini E., Hamilton A. et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 697–714. DOI: 10.2147/COPD.S62502.

54. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486. DOI: 10.1016/S2213-2600(14)70065-7.

55. Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations in COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI: 10.1056/NEJMoa1008378.

56. Decramer M.L., Chapman K.R., Dahl R. et al. INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI: 10.1016/S2213-2600(13)70158-9.

57. Wilchesky M., Ernst P., Brophy J.M. et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012; 142 (2): 305–311. DOI: 10.1378/chest.11-1597.

58. Decramer M.L., Hanania N.A., Lotvall J.O., Yawn B.P. The safety of long-acting b2-agonists in the treatment of stable chronic obstructive disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 53–64. DOI: 10.2147/COPD.S39018.

59. Kew K.M., Mavergames C., Walters J.A.E. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (10): CD010177. DOI: 10.1002/14651858.CD010177.pub2.

60. Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD009285. DOI: 10.1002/14651858.CD009285.pub2.

61. Sims M.W., Panettieri R.A. Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 457–466. DOI: 10.2147/COPD.S15524.

62. Ulrik C.S. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 673–678. DOI: 10.2147/COPD.S35990.

63. Jones P.W., Rennard S.I., Agusti A. et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir. Res. 2011; 12 (1): 55. DOI: 10.1186/1465-9921-12-55.

64. Kerwin E., Hebert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40 (5): 1106–1114. DOI: 10.1183/09031936.00040712.

65. Donohue J.F., Niewoehner D., Brooks J. et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, doubleblind, placebo-controlled study. Respir. Res. 2014; 15 (1): 78. DOI: 10.1186/1465-9921-15-78.

66. Sharafkhaneh A., Majid H., Gross N.J. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf. 2013; 5: 49–55. DOI: 10.2147/DHPS.S7771.

67. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554. DOI: 10.1056/NEJMoa0805800.

68. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501. DOI: 10.1056/NEJMoa1303342.

69. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (2): CD001387. DOI: 10.1002/14651858.CD001387.pub2.

70. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (3): CD006101. DOI: 10.1002/14651858.CD006101.

71. Karner C., Cates C.J. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; (10): CD008989. DOI: 10.1002/14651858.cd008989.pub3.

72. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486. DOI: 10.1016/S2213-2600(14)70065-7.

73. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.

74. Donohue J.F., Maleki-Yazdi M.R., Kilbride S. et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546. DOI: 10.1016/j.rmed.2013.06.001.

75. Vincken W., Aumann J., Chen H. et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 215–228. DOI: 10.2147/COPD.S51592.

76. Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir. Med. 2014; 108 (10): 1498–1507. DOI: 10.1016/j.rmed.2014.07.011.

77. Ulrik C.S. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 331–338. DOI: 10.2147/COPD.S60362.

78. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45 (4): 969–979. DOI: 10.1183/09031936.00136014.

79. Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm. Med. 2014; 14: 178. DOI: 10.1186/1471-2466-14-178.

80. Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53–59. DOI: 10.1016/j.pupt.2015.04.002.

81. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.

82. Broekhuizen B.D., Sachs A.P., Moons K.G. et al. Diagnostic value of oral prednisolone test for chronic obstructive pulmonary disorders. Ann. Fam. Med. 2011; 9 (2): 104–109. DOI: 10.1370/afm.1223.

83. Callahan C.M., Dittus R.S., Katz B.P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann. Intern. Med. 1991; 114 (3): 216–23. DOI: 10.7326/0003-4819-114-3-216.

84. Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 2012 (7): CD002991. DOI: 10.1002/14651858.CD002991.pub3.

85. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001– 1006. DOI: 10.1016/j.amjmed.2010.06.019.

86. Izquierdo J.L., Cosio B. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int. J. COPD. 2018; 13: 3539–3547. DOI: 10.2147/COPD.S175047.

87. Calverley P.M.A., Anderson A.M.A., Ferguson G.T. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789. DOI: 10.1056/NEJMoa063070.

88. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.

89. Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438–446. DOI: 10.1164/rccm.201703-0449OC.

90. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann. Intern. Med. 2007; 146 (8): 545–555. DOI: 10.7326/0003-4819-146-8-200704170-00152.

91. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (8): 741–750. DOI: 10.1164/rccm.200904-0492OC.

92. Cazzola M., Ando F., Santus P. et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium to the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 2007; 20 (5): 556–561. DOI: 10.1016/j.pupt.2006.06.001.

93. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (3): CD008532. DOI: 10.1002/14651858.CD008532.pub2.

94. Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI: 10.1164/rccm.200707-973OC.

95. Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390–398. DOI: 10.1016/S2213-2600(16)00100-4.

96. Vestbo J., Anderson J.A., Brook R.D. et al. SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016; 387 (10030): 1817–1826. DOI: 10.1016/S0140-6736(16)30069-1.

97. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI: 10.1136/thx.2011.160028.

98. Chong J., Poole P., Leung B., Black P.N. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (5): CD002309. DOI: 10.1002/14651858.CD002309.pub3.

99. Calverley P.M.A., Rabe K.F., Goehring U.M et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374 (9691): 685–694. DOI: 10.1016/S0140-6736(09)61255-1.

100. Walters J.A.E., Walters E.H., Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005; (3): CD005374. DOI: 10.1002/14651858.CD005374.

101. Schols A.M.W.J., Wesseling G., Kester A.D.M. et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur. Respir. J. 2001; 17 (3): 337–342. DOI: 10.1183/09031936.01.17303370.

102. Man W.D.C., Kemp P., Moxham J., Polkey M.I. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin. Sci. (Lond.). 2009; 117 (7): 251–264. DOI: 10.1042/CS20080659.

103. Barnes P.J. Theophylline. Am. J. Respir. Crit. Care Med. 2013; 188 (8): 901–906. DOI: 10.1164/rccm.201302-0388PP.

104. Zhou Y., Wang X., Zeng X. et al. Positive benefits of theophylline in a randomized, double-blind, parallelgroup, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006; 11 (5): 603–610. DOI: 10.1111/j.1440-1843.2006.00897.x.

105. Ram F.S., Jones P., Jardim J. et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002; 2002 (4): CD003902. DOI: 10.1002/14651858.CD003902.

106. Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002; 121 (4): 1058–1069. DOI: 10.1378/chest.121.4.1058.

107. Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A metaanalysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir. Med. 2013; 107 (9): 1385–1392. DOI: 10.1016/j.rmed.2013.05.004.

108. Albert R.K., Connett J., Bailey W.C. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365 (8): 689–698. DOI: 10.1056/NEJMoa1104623.

109. Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015; 24 (137): 451–461. DOI: 10.1183/16000617.00002215.

110. Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (8): CD001287. DOI: 10.1002/14651858.CD001287.pub4.

111. Al-Showair R.A., Tarsin W.Y., Assi K.H. et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir. Med. 2007; 101 (11): 2395–2401. DOI: 10.1016/j.rmed.2007.06.008.

112. Zeng Z., Yang D., Huang X., Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 2277–2283. DOI: 10.2147/COPD.S140603.

113. Wieshammer S., Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008; 75 (1): 18–25. DOI: 10.1159/000109374.

114. Chapman K.R., Voshaar T.H., Virchow J.C. Inhaler choice in primary practice. Eur. Respir. Rev. 2005; 14 (96): 117–122. DOI: 10.1183/09059180.05.00009607.

115. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (1): CD002733. DOI: 10.1002/14651858.CD002733.pub2.

116. Sestini P., Renzoni E., Robinson S. et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002; (4): CD001495. DOI: 10.1002/14651858.CD001495.

117. Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21 (1): 101–108. DOI: 10.4104/pcrj.2011.00102.

118. Mahler D.A., Decramer M., D`Urzo A. et al. Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013.

119. Calzetta L., Ritondo B.L., de Marco P. et al. Evaluating triple ICS/ LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Exp. Rev. Respir. Med. 2021; 15 (1): 143–152. DOI: 10.1080/17476348.2020.1816830.

120. Yu A.P., Guérin A., Ponce de Leon D. et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J. Med. Econ. 2011; 14 (4): 486–496. DOI: 10.3111/13696998.2011.594123.

121. White P., Thorntoh H., Pinnock H. et al. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS ONE. 2013; 8 (10): e75221. DOI: 10.1371/journal.pone.0075221.

122. Rossi A., Guerriero M., Corrado A. OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res. 2014; 15 (1): 77. DOI: 10.1186/1465-9921-15-77.

123. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI: 10.1056/NEJMoa1407154.

124. Chapman K.R., Hurst J.R., Frent S.M. et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 2018; 198 (3): 329–339. DOI: 10.1164/rccm.201803-0405OC.

125. Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Отмена ингаляционных глюкокортикостероидов у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2019; 29 (3): 334–345. DOI: 10.18093/0869-0189-2019-29-3-334-345.

126. Naunheim K.S., Wood D.E., Mohsenifar Z. et al. Long-term follow-up of patients receiving lung-volume reduction surgery versus medical therapy for severe emphysema by the national emphysema treatment trial research group. Ann. Thorac. Surg. 2006; 82 (2): 431–443. DOI: 10.1016/j.athoracsur.2006.05.069.

127. Orens J.B., Estenne M., Arcasoy S. et al. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2006; 25 (7): 745–755. DOI: 10.1016/j.healun.2006.03.011.

128. Stoller J.K., Panos R.J., Krachman S. et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest. 2010; 138 (1): 179–187. DOI: 10.1378/chest.09-2555.

129. Sculley J. A., Corbridge S. J., Prieto-Centurion V. et al. Home oxygen therapy for patients with COPD: Time for a Reboot. Respir. Care. 2019; 64 (12): 1574–1585. DOI: 10.4187/respcare.07135.

130. Ergan B., Nava S. Long-term oxygen therapy in copd patients who do not meet the actual recommendations. COPD: J. Chron. Obstruct. Pulmon. Dis. 2017; 14 (3): 351–366. DOI: 10.1080/15412555.2017.1319918.

131. Jacobs S.S., Krishnan J.A., Lederer D.J. et al. Home oxygen therapy for adults with chronic lung disease: An Official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020; 202 (10): e121–141. DOI: 10.1164/rccm.202009-3608ST.

132. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1995; 152 (5, Pt 2): 77–120. Available at: https://www.thoracic.org/statements/resources/copd1-45.pdf

133. Murphy P.B., Rehal S., Arbane G. et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomised clinical trial. JAMA. 2017; 317 (21): 2177–2186. DOI: 10.1001/jama.2017.4451.

134. Kohnlein T., Windish W., Kohler D. et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicenter, randomized controlled clinical trial. Lancet Respir. Med. 2014; (9): 698–705. DOI: 10.1016/S2213-2600(14)70153-5.

135. Ergan B., Oczkowski S., Rochwerg B. et al. European Respiratory Society guideline on long-term home non-invasive ventilation for management of chronic obstructive pulmonary disease. Eur. Respir. J. 2019; 54 (3): 1901003. DOI: 10.1183/13993003.01003-2019.

136. Duiverman M. L., Vonk J. M., Bladder G. et al. Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. Thorax. 2020; 75 (3): 244–252. DOI: 10.1136/thoraxjnl-2019-213303.

137. Murphy P. B., Hart N. Home non-invasive ventilation for COPD: how, who and when? Arch. Bronconeumol. (Engl. Ed.) 2018; 54 (3): 149–154. DOI: 10.1016/j.arbres.2017.12.005.

138. McEvoy R.D., Pierce R.J., Hillman D. et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009: 64 (7): 561–566. DOI: 10.1136/thx.2008.108274.

139. NICE Clinical Guidelines Centre (UK). Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: Royal College of Physicians (UK); 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65039/

140. Higgings B.G., Powell R.M., Cooper S., Tattersfield A.E. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur. Respir. J. 1991; 4 (4): 415–420.

141. O’Driscoll B.R., Kay E.A., Taylor R.J. et al. A long-term prospective assessment of home nebulizer treatment. Respir. Med. 1992; 86 (4): 317–325. DOI: 10.1016/s0954-6111(06)80031-4.

142. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999; 354 (9177): 456–460. DOI: 10.1016/s0140-6736(98)11326-0.

143. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2002: 165 (5): 698–703. DOI: 10.1164/ajrccm.165.5.2109093.

144. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 48–55. DOI: 10.1164/rccm.201108-1553OC.

145. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106 (2): 196–204. DOI: 10.7326/0003-4819-106-2-196.

146. Miravitlles M., Kruesmann F., Haverstock D. et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur. Respir. J. 2012; 39 (6): 1354–1360. DOI: 10.1183/09031936.00042111.

147. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001; 358 (9298): 2020–2025. DOI: 10.1016/S0140-6736(01)07097-0.

148. Weis N., Almdal T. C-reactive protein – can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17 (2): 88–91. DOI: 10.1016/j.ejim.2005.09.020.

149. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92 (4): 664–667. DOI: 10.1016/s0954-6111(98)90515-7.

150. Авдеев С.Н. Обострения хронической обструктивной болезни легких: выбор антибактериальной терапии. Пульмонология. 2014; (6): 65–72. DOI: 10.18093/0869-0189-2014-0-6-65-72.

151. Wise R.A. Treatment of acute COPD exacerbation. Last full review/ revision Jun. 2020. Available at: https://www.merckmanuals.com/professional/pulmonary-disorders/chronic-obstructive-pulmonary-disease-and-related-disorders/treatment-of-acute-copd-exacerbation

152. Miravitlles M., Espinosa C., Fernandez-Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999; 116 (1): 40–46. DOI: 10.1378/chest.116.1.40.

153. Yoon H.I., Lee C.H., Kim D.K. et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 329–334. DOI: 10.2147/COPD.S41749.

154. Wilson R., Anzueto A., Miravitlles M. et. al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur. Respir. J. 2012; 40 (1): 17–27. DOI: 10.1183/09031936.00090311.

155. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiologyand lung function. Chest. 1998; 113 (6): 1542–1548. DOI: 10.1378/chest.113.6.1542.

156. Austin M.A., Wills K.E., Blizzard L. et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010; 341: c5462. DOI: 10.1136/bmj.c5462.

157. Anton A., Guell R., Gymes J. et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation. Chest. 2000; 117 (3): 828–833. DOI: 10.1378/chest.117.3.828.

158. Plant P.K., Owen J.L., Elliott M.W. Early use of non-invasive ventilationfor acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000; 355 (9219): 1931–1935. DOI: 10.1016/s0140-6736(00)02323-0.

159. Mehta S., Hill N.S. Noninvasive ventilation. Am. J. Respir. Crit. Care Med. 2001; 163 (2): 540–577. DOI: 10.1164/ajrccm.163.2.9906116.

160. Авдеев С.Н., Чучалин А.Г. Неинвазивная вентиляция легких при острой дыхательной недостаточности у больных хронической обструктивной болезнью легких. Терапевтический архив. 2000; (3): 59–65.

161. Nava S., Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009; 374 (9885): 250–259. DOI: 10.1016/S0140-6736(09)60496-7.

162. Conti G., Antonelli M., Navalesi P. et al. Noninvasive vs. conventional mechanical ventilationin patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomised trial. Intensive Care Med. 2002; 28 (12): 1701–1707. DOI: 10.1007/s00134-002-1478-0.

163. Gladwin M.T., Pierson D.J. Mechanical ventilation of the patient with severe chronic obstructive pulmonary disease. Intensive Care Med. 1998; 24 (9): 898–910. DOI: 10.1007/s001340050688.

164. Esteban A., Frutos F., Tobin M.J. et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish lung failure collaborative group. N. Engl. J. Med. 1995; 332 (6): 345–350. DOI: 10.1056/NEJM199502093320601.

165. Vargas F., Bui H.N., Boyer A. et al. Intrapulmonary percussive ventilation in acute exacerbations of COPD patients with mild respiratory acidosis: a randomized controlled trial [ISRCTN17802078]. Crit. Care. 2005; 9: R382. DOI: 10.1186/cc3724.

166. Авдеев С.Н., Гусева Н.А., Нуралиева Г.С. Эффективность метода высокочастотных колебаний грудной стенки при обострении хронической обструктивной болезни легких. Пульмонология. 2016; 26 (4): 466–472. DOI: 10.18093/0869-0189-2016-26-4-466-472.

167. Waschki B., Kirsten A., Holz O. et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140 (2): 331–342. DOI: 10.1378/chest.10-2521.

168. Nici L., Donner C., Wouters E. et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173 (12): 1390–1413. DOI: 10.1164/rccm.200508-1211ST.

169. Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S–42S. DOI: 10.1378/chest.06-2418.

170. Puhan M.A., Gimeno-Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD005305. DOI: 10.1002/14651858.CD005305.pub3.

171. Celli B.R. Pulmonary rehabilitation in patients with COPD. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 861–864. DOI: 10.1164/ajrccm.152.3.7663796.

172. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172 (1): 19–38. DOI: 10.1164/rccm.200408-1109SO.

173. Puhan M.A., Busching G., Schunemann H.J. et al. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2006; 145 (11): 816–825. DOI: 10.7326/0003-4819-145-11-200612050-00006.

174. Mahler D.A. Pulmonary rehabilitation. Chest. 1998; 113 (4, Suppl): 263S–268S. DOI: 10.1378/chest.113.4_supplement.263s.

175. Belman M.J., Botnick W.C., Nathan S.D., Chon K.H. Ventilatory load characteristics during ventilatory muscle training. Am. J. Respir. Crit. Care Med. 1994; 149 (4, Pt 1): 925–929. DOI: 10.1164/ajrccm.149.4.8143057.

176. O’Brien K., Geddes E.L., Reid W.D. et al. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. J. Cardiopulm. Rehabil. Prev. 2008; 28 (2): 128–141. DOI: 10.1097/01.HCR.0000314208.40170.00.

177. Heffner J.E., Fahy B., Hilling L., Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am. J. Respir. Crit. Care Med. 1997; 155 (3): 1055–1059. DOI: 10.1164/ajrccm.155.3.9116986.

178. Zwerink M., Brusse-Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; 2014 (3): CD002990. DOI: 10.1002/14651858.CD002990.pub3.

179. Bischoff E.W., Hamd D.H., Sedeno M. et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax. 2011; 66 (1): 26–31. DOI: 10.1136/thx.2009.127621.

180. Van Eerd E.A., van der Meer R.M., van Schayk O.C., Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2016; 2016 (8): CD010744. DOI: 10.1002/14651858.CD010744.pub2.

181. Romieu I., Riojas-Rodriguez H., Marron-Mares A.T. et al. Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women. Am. J. Respir. Crit. Care Med. 2009; 180 (7): 649–656. DOI: 10.1164/rccm.200810-1556OC.

182. Mathew T., Kaur A., Ross J. For patients with COPD, does pneumococcal vaccination reduce the incidence of pneumococcal pneumonia? Evidence-Based Practice. 2018; 21 (1): Е15. DOI: 10.1097/01.EBP.0000541953.43152.a6.

183. Sandelowsky H., Natalishvili N., Krakau I. et al. COPD management by Swedish general practitioners – baseline results of the PRIMAIR study. Scand. J. Prim. Health Care. 2018; 36 (1): 5–13. DOI: 10.1080/02813432.2018.1426148.

184. Jochmann A., Neubauer F., Miedinger D. et al. General practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med. Wkly. 2010; 140: 13053. DOI: 10.4414/smw.2010.13053.

185. Ragaišienė G., Kibarskytė R., Gauronskaitė R. et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip. Respir. Med. 2019; 14: 28. DOI: 10.1186/s40248-019-0191-6.

186. Matsunaga K., Oishi K., Miravitlles M., Anzueto A. Time to revise COPD treatment algorithm. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 2229–2234. DOI: 10.2147/COPD.S219051.

187. Белевский А.С. Организация и проведение обучения больных хронической обструктивной болезнью легких: методические рекомендации. М.: Атмосфера; 2003.

188. Schermer T., Smeenk F., van Weel C. Referral and consultation in asthma and COPD: an exploration of pulmonologists’ views. Neth. J. Med. 2003; 61 (3): 71–81.

189. Oliveira A.S., Munhá J., Bugalho A. et al. Identification and assessment of COPD exacerbations. Pulmonology. 2018; 24 (1): 42–47. DOI: 10.1016/j.rppnen.2017.10.006.

190. Walters J. A. E. et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2017; 1 (1): CD001390. DOI: 10.1002/14651858.CD001390.pub4.

191. Авдеев С.Н. Длительная кислородотерапия при хронической дыхательной недостаточности. М.: ФГУ «НИИ пульмонологии ФМБА» России; 2011.

192. Авдеев С.Н. Неинвазивная вентиляция легких у пациентов с хронической обструктивной болезнью легких в стационаре и домашних условиях. Пульмонология. 2017; 27 (2): 232–249. DOI: 10.18093/0869-0189-2017-27-2-232-249.

193. Milačić N., Milačić B., Dunjic O. et al. Validity of CAT and mMRC – dyspnea score in evaluation of COPD severity. Acta Medica Medianae. 2015; 54 (1): 66–70. Available at: https://www.semanticscholar.org/paper/VALIDITY-OF-CAT-AND-MMRC-%E2%80%93-DYSPNEASCORE-IN-OF-COPD-Milaci%C4%87-Milaci%C4%87/fe7f485730f84d73ca35acd03b284ec19b86417a

194. Mahler D.A., Faryniarz K., Tomlinson D. et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest. 1992; 102 (2): 395–401. DOI: 10.1378/chest.102.2.395.

195. Gruffydd-Jones K., Marsden H.C., Holmes S. et al. Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial. Prim. Care Respir. J. 2013; 22 (1): 37–43. DOI: 10.4104/pcrj.2013.00001.

196. Grouse L., DeWeerdt S., eds. IPAG Diagnosis and Management Handbook. Chronic Airways Diseases: A Guide for Primary Care Physicians. Edgewater, MCR Vision, Inc.; 2005.

197. Celli B.R. Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. Chest. 2006; 129 (4): 835–836. DOI: 10.1378/chest.129.4.835.


Рецензия

Для цитирования:


Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):356-392. https://doi.org/10.18093/0869-0189-2022-32-3-356-392

For citation:


Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2022;32(3):356-392. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-3-356-392

Просмотров: 145


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)